Subsequently, many studies have tried to elucidate the mechanisms through which Sfrp5 and Wnt5a are associated with obesity and cardiometabolic risk factors, as well as their potential role in developing new pharmaceutical compounds. Here, WNT5A is linked to obesity disorder.